A State-of-the-Art Roadmap for Biomarker-Driven Drug Development in the Era of Personalized Therapies

Abstract excerpt

Advances in biotechnology have enabled us to assay human tissue and cells to a depth and resolution that was never possible before, redefining what we know as the "biomarker", and how we define a "disease". This comes along with the shift of focus from a "one-drug-fits-all" to a "personalized approach", placing the drug development industry in a highly dynamic landscape, having to navigate such disruptive trends....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Genomics and Diagnostics
• Share to CAR-T cell therapy research
• Share to Computational Drug Discovery Methods